The stock of Aurinia Pharmaceuticals Inc (AUPH) has seen a 1.52% increase in the past week, with a -0.62% drop in the past month, and a -7.38% decrease in the past quarter. The volatility ratio for the week is 1.96%, and the volatility levels for the past 30 days are at 1.42% for AUPH. The simple moving average for the last 20 days is 0.07% for AUPH’s stock, with a simple moving average of 0.43% for the last 200 days.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has a higher price-to-earnings ratio of 29.07x compared to its average ratio, The 36-month beta value for AUPH is at 1.16. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AUPH is 119.37M, and currently, shorts hold a 8.79% of that float. The average trading volume for AUPH on June 26, 2025 was 1.22M shares.
AUPH) stock’s latest price update
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has dropped by -0.25 in relation to previous closing price of 8.05. Nevertheless, the company has seen a gain of 1.52% in its stock price over the last five trading days. zacks.com reported 2025-05-30 that Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at -0.13% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.74% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Keenan Greg, who sale 8,305 shares at the price of $8.23 back on Mar 07 ’25. After this action, Keenan Greg now owns 153,484 shares of Aurinia Pharmaceuticals Inc, valued at $68,350 using the latest closing price.
Greenleaf Peter, the Chief Executive Officer of Aurinia Pharmaceuticals Inc, sale 195,593 shares at $8.00 during a trade that took place back on Mar 03 ’25, which means that Greenleaf Peter is holding 1,953,892 shares at $1,564,744 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.88 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at 0.16. The total capital return value is set at 0.07. Equity return is now at value 11.23, with 7.80 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.83. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 12.55.
Currently, EBITDA for the company is 31.73 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 4.43. The receivables turnover for the company is 6.13for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.93.
Conclusion
In conclusion, Aurinia Pharmaceuticals Inc (AUPH) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
